PolarityBio files BLA for SkinTE in diabetic foot ulcers
PolarityBio has submitted a Biologics License Application to the US Food and Drug Administration for SkinTE (autologous cutaneous multicellular units), targeting Wagner Grade 1 diabetic foot ulcers. The Salt Lake City company said the filing follows the successful completion of its pivotal Phase III randomised controlled trial, COVER DFUS II, which met its primary endpoint of complete wound closure within 12 weeks.
SkinTE holds both Regenerative Medicine Advanced Therapy and Breakthrough Therapy designations from the FDA, reflecting the agency's prior assessment of the product's potential to address a serious unmet need. The therapy is designed to use a patient's own full-thickness skin to activate regenerative processes at the wound site, positioning it as an autologous rather than allogeneic approach.
Trial design and data
COVER DFUS II (NCT06140303) enrolled 120 patients across multiple US clinical sites over 14 months. Participants were randomised 1:1 to receive SkinTE plus standard of care, or standard of care alone, and were followed for 24 weeks. Eligibility required a wound of at least four weeks' duration that had not responded to prior treatment, alongside a two-week run-in period under rigorous standard of care; only patients whose ulcer did not change in size by more than 30% during the run-in progressed to randomisation.
The company has not yet released the full dataset, including the absolute wound-closure rates in each arm, safety outcomes, or subgroup breakdowns. Those figures will be critical for clinicians and payers assessing the therapy's clinical value proposition against existing advanced wound care products.
Nikolai Sopko, chief operating officer and chief scientific officer of PolarityBio, said the BLA submission represented "a defining moment" for the company and for patients living with the burden of diabetic foot ulcers. Robert Kirsner, chair of the COVER DFUS II trial, noted that when standard care fails, ulcers frequently progress, raising mortality risk and increasing the likelihood of amputation.
Regulatory and market context
The chronic wound care market is a sizeable but historically underserved space. The company's claim that SkinTE would be the first new biologic commercially available in the United States for a chronic wound indication in nearly 30 years, if approved, reflects how little regulatory progress has been made in this category relative to its clinical burden. A BLA filing rather than a PMA or 510(k) pathway is consistent with the autologous cellular nature of the product.
The reimbursement environment adds a meaningful commercial dimension to the approval question. Restructuring of the Centers for Medicare and Medicaid Services payment framework for wound care products took effect in January 2026, introducing significant uncertainty for many advanced wound care technologies. PolarityBio has highlighted that products approved under a BLA are generally excluded from those changes and would continue to attract biologic reimbursement rates under existing methodology, which could represent a structural pricing advantage over non-BLA competitors.
Beyond the DFU indication, the company is advancing SkinTE for venous leg ulcers and pressure injuries, suggesting the BLA filing is intended as a commercial and clinical platform, not a single-indication asset. The FDA review clock will begin from acceptance of the filing; the standard review period for a BLA is 12 months, with a priority review pathway of six months potentially available given the Breakthrough Therapy designation. Near-term milestones to watch include an FDA filing acceptance letter, any advisory committee meeting, and the release of the full COVER DFUS II dataset at a medical conference.